Chronic bromocriptine treatment and glucose intolerance in acromegaly. 1985

V Popović, and D Micić, and M Nesović, and P Djordjević, and J Mićić, and D S Djurić

Blood glucose, plasma GH, insulin and glucagon levels during OGTT before and after treatment with bromocriptine (20 - 40 mg daily 3 - 18 months) were studied in 12 nondiabetic acromegalics (NA) and 6 diabetic acromegalics (DA) not treated previously. There was no significant change in blood glucose levels before and after treatment in NA while blood glucose levels fell significantly in DA after treatment. Mean basal GH levels and after OGTT decreased significantly in NA group, while only in the 120 min of OGTT in DA group. There was no significant change in mean basal or glucose stimulated plasma insulin or glucagon levels before and after treatment in both non-diabetic and diabetic acromegalics. Normal glucagon levels in diabetic acromegalics prior to treatment is considered as relative hyperglucagonaemia which disappeared after treatment. We did not show that glucagon suppressibility after OGTT was reestablished after treatment with bromocriptine in non-diabetic and diabetic acromegalics. Other factors than changes in hormones should be considered as a cause of restored glucose tolerance.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D001971 Bromocriptine A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion. 2-Bromoergocryptine,Bromocryptin,2-Bromo-alpha-ergocryptine,2-Bromo-alpha-ergokryptine,2-Bromoergocryptine Mesylate,2-Bromoergocryptine Methanesulfonate,2-Bromoergokryptine,Bromocriptin,Bromocriptine Mesylate,CB-154,Parlodel,2 Bromo alpha ergocryptine,2 Bromo alpha ergokryptine,2 Bromoergocryptine,2 Bromoergocryptine Mesylate,2 Bromoergocryptine Methanesulfonate,2 Bromoergokryptine,CB 154,CB154,Mesylate, 2-Bromoergocryptine,Mesylate, Bromocriptine,Methanesulfonate, 2-Bromoergocryptine
D003920 Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
D005260 Female Females
D005934 Glucagon A 29-amino acid pancreatic peptide derived from proglucagon which is also the precursor of intestinal GLUCAGON-LIKE PEPTIDES. Glucagon is secreted by PANCREATIC ALPHA CELLS and plays an important role in regulation of BLOOD GLUCOSE concentration, ketone metabolism, and several other biochemical and physiological processes. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1511) Glucagon (1-29),Glukagon,HG-Factor,Hyperglycemic-Glycogenolytic Factor,Proglucagon (33-61),HG Factor,Hyperglycemic Glycogenolytic Factor
D005951 Glucose Tolerance Test A test to determine the ability of an individual to maintain HOMEOSTASIS of BLOOD GLUCOSE. It includes measuring blood glucose levels in a fasting state, and at prescribed intervals before and after oral glucose intake (75 or 100 g) or intravenous infusion (0.5 g/kg). Intravenous Glucose Tolerance,Intravenous Glucose Tolerance Test,OGTT,Oral Glucose Tolerance,Oral Glucose Tolerance Test,Glucose Tolerance Tests,Glucose Tolerance, Oral
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

V Popović, and D Micić, and M Nesović, and P Djordjević, and J Mićić, and D S Djurić
February 1982, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
V Popović, and D Micić, and M Nesović, and P Djordjević, and J Mićić, and D S Djurić
February 1975, British medical journal,
V Popović, and D Micić, and M Nesović, and P Djordjević, and J Mićić, and D S Djurić
May 1977, Metabolism: clinical and experimental,
V Popović, and D Micić, and M Nesović, and P Djordjević, and J Mićić, and D S Djurić
June 1979, Australian and New Zealand journal of medicine,
V Popović, and D Micić, and M Nesović, and P Djordjević, and J Mićić, and D S Djurić
November 1978, The Medical journal of Australia,
V Popović, and D Micić, and M Nesović, and P Djordjević, and J Mićić, and D S Djurić
May 1979, Drugs,
V Popović, and D Micić, and M Nesović, and P Djordjević, and J Mićić, and D S Djurić
May 1993, The Clinical investigator,
V Popović, and D Micić, and M Nesović, and P Djordjević, and J Mićić, and D S Djurić
November 2001, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas,
V Popović, and D Micić, and M Nesović, and P Djordjević, and J Mićić, and D S Djurić
October 1981, The New England journal of medicine,
V Popović, and D Micić, and M Nesović, and P Djordjević, and J Mićić, and D S Djurić
February 1986, Clinical endocrinology,
Copied contents to your clipboard!